Invivyd (NASDAQ:IVVD) Earns Buy Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Invivyd (NASDAQ:IVVD) in a report issued on Friday morning,Benzinga reports. D. Boral Capital currently has a $9.00 price objective on the stock.

IVVD has been the topic of a number of other research reports. EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. HC Wainwright cut their price target on Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. Finally, Morgan Stanley lowered their price objective on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research note on Wednesday, November 20th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $7.89.

Invivyd Trading Down 2.1 %

IVVD stock opened at $0.45 on Friday. The company’s 50-day moving average price is $0.64 and its 200 day moving average price is $0.91. Invivyd has a 52 week low of $0.40 and a 52 week high of $5.20. The company has a market cap of $54.07 million, a P/E ratio of -0.23 and a beta of 0.64.

Insider Buying and Selling

In other Invivyd news, Director Terrance Mcguire sold 160,400 shares of the business’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $0.59, for a total value of $94,636.00. Following the completion of the transaction, the director now directly owns 4,202,679 shares in the company, valued at approximately $2,479,580.61. The trade was a 3.68 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last quarter, insiders sold 816,466 shares of company stock worth $423,214. 17.90% of the stock is owned by corporate insiders.

Institutional Trading of Invivyd

A number of hedge funds have recently added to or reduced their stakes in IVVD. Proficio Capital Partners LLC acquired a new stake in shares of Invivyd in the third quarter worth approximately $27,000. XTX Topco Ltd increased its holdings in shares of Invivyd by 68.1% during the 2nd quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock worth $42,000 after buying an additional 15,376 shares during the last quarter. Cornercap Investment Counsel Inc. purchased a new position in shares of Invivyd in the 2nd quarter worth $86,000. Rhumbline Advisers boosted its holdings in Invivyd by 4,434.1% in the second quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock valued at $92,000 after acquiring an additional 82,164 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in Invivyd during the second quarter valued at about $115,000. 70.36% of the stock is owned by institutional investors and hedge funds.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.